Purchase this article with an account.
A. Polito, P. Lanzetta, D. Roman Pognuz, I. Paissios, F. Bandello; Subtenon Triamcinolone for Refractory Diabetic Macular Edema . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1448.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the effect of subtenon injection of triamcinolone acetonide (TA) for the treatment of diabetic macular edema unresponsive to previous laser treatment. Methods: This retrospective, clinical case series included 9 consecutive patients (9 eyes) who received a subtenon injection of 1 ml of 40 mg of TA. Main outcome measures were measurement of foveal thickening (FTH) with optical coherence tomography (OCT), change in Snellen visual acuity (LogMAR equivalent) and intraoculare pressure. Results: Nine eyes completed 1 month, 7 eyes 3 months and 4 eyes 6 months of follow–up. Mean (SD) FTH decreased from 488 (123) µm at baseline to 385 (104) µm, 378 (93) µm and 344 (24) µm at the 1, 3, and 6 month follow up period, respectively. Mean (SD) visual acuity improved from 0.53 (0.22) at baseline to 0.38 (0.14 ), 0.37 (0.18), and 0.33 (0.10) at the 1, 3, and 6 month of follow up, respectively. No change in intraocular pressure occurred. Conclusions: Subtenon TA appears to be a possibly effective and safe treatment in patients with refractory diabetic macular edema, at least in the short term. The simple route of administration and the possibility of multiple injection give interest to this treatment.
This PDF is available to Subscribers Only